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Abstract 
Glioblastoma multiforme (GBM) is the commonest primary brain tumour in adults characterized 
by relentless recurrence due to resistance towards the standard chemotherapeutic agent te-
mozolomide (TMZ). Prolyl 4-hydroxylase, beta polypeptide (P4HB), an endoplasmic reticulum 
(ER) chaperone, is known to be upregulated in TMZ-resistant GBM cells. MicroRNAs (miRNAs) 
are non-protein-coding transcripts that may play important roles in GBM chemoresistance. We 
surmised that miRNA dysregulations may contribute to P4HB upregulation, hence chemo-
resistance. We found that miRNA-210 (miR-210) was P4HB-targeting and was highly downregu-
lated in TMZ-resistant GBM cells. Forced overexpression of miR-210 led to P4HB downregulation 
and a reduction in TMZ-resistance. A reciprocal relationship between their expressions was also 
verified in clinical glioma specimens. Our study is the first to demonstrate a potential link between 
miR-210 and ER chaperone in determining chemosensitivity in GBM. The findings have important 
translational implications in suggesting new directions of future studies. 
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Introduction 
Glioblastoma multiforme (GBM), a World 
Health Organization (WHO) Grade IV glioma, is the 
commonest and most malignant form of primary 
brain tumour [1-3]. GBM is highly invasive and re-
fractory towards the standard chemotherapeutic 
agent temozolomide (TMZ), resulting in high recur-
rence and mortality rates [4]. 
 Prolyl 4-hydroxylase, beta polypeptide (P4HB) 
is a chaperone protein of the endoplasmic reticulum 
stress response (ERSR) pathway. While its normal 
function is to prevent unfolded protein aggregation, 
P4HB has also been found to prevent chemothera-
peutics-induced apoptosis in cancer cells [5, 6]. In-
deed, our group have previously identified P4HB to 
be highly expressed in TMZ-resistant GBM cells [7]. 
This conferred TMZ-resistance by suppressing the 
activation of the downstream ERSR pathway that 
would otherwise induce apoptosis [8]. 
 MicroRNAs (miRNAs) are small, non-coding 
RNAs about 22 nucleotides long. They regulate gene 
expression post-transcriptionally by binding to the 3’ 
untranslated region (3’ UTR) of the target genes and 
cause messenger RNA (mRNA) degradation and/or 
translation inhibition [9, 10]. Dysregulated miRNA 
expressions are found in various cancers and are in-
timately involved in cancer progression [11]. Hypoxia 
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is an important inducer of ERSR in GBM and is also 
commonly associated with miRNA dysregulation. For 
instance, miR-210 is consistently upregulated under 
hypoxia and highly dysregulated in GBM, but its role 
in GBM chemoresistance has not been studied [12, 13]. 
Interestingly, miR-210 is also known to target P4HB 
[14]. We therefore conducted the present study to 
investigate whether and how miR-210 may interact 
with the ERSR pathway, in particular its chaperone 
protein P4HB, in affecting GBM response to TMZ. The 
hypothesis was that miR-210 would be downregu-
lated in TMZ-resistant cells and that its upregulation 
would improve chemoresponsiveness.  
Methods and Materials 
GBM cell culture and TMZ-resistant subclones 
Two human GBM cell lines were used: D54-MG 
(a gift from Duke University Medical Center, 
Durham, NC, USA) and U87-MG (American Type 
Culture Collection, Manassas, VA, USA). D54-MG 
cells were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM)/F-12, and U87-MG in Minimum 
Essential Medium (MEM) α, all of which were sup-
plemented with 10% fetal bovine serum (FBS) and 1% 
Penicillin-Streptomycin (PS) (all from Gibco® by Life 
Technologies, Grand Island, NY, USA). Both cell lines 
were cultured in a 37°C humidified incubator with 5% 
CO2. Isogenic TMZ-resistant subclones D54-R and 
U87-R were derived after chronic exposure of the pa-
rental cells D54-S and U87-S to TMZ (Temodal; 
Schering-Plough Corporation, Kenilworth, NJ, USA) 
as previously described [7]. 
Clinical glioma tumour samples 
 Clinical tumour samples were collected from 
patients who had undergone initial surgical resection 
before chemo-irradiation and adjuvant TMZ treat-
ment. Tissues of WHO grade II to IV, confirmed by a 
neuropathologist, were used. The study was ap-
proved by the Institution Review Board of our insti-
tution and signed consent forms by patients or their 
legal guardians were obtained. 
Quantitative real-time polymerase chain re-
action (qPCR) 
Relative expression levels of miR-210 and P4HB 
in vitro and in clinical specimens were quantified by 
qPCR. MiRNA and total RNA were extracted using 
the TRIzol® Reagent (Ambion® by Life Technologies, 
Austin, TX, USA). Purified miRNA and RNA samples 
were reverse-transcribed using miScript® IIl RT Kit 
(Qiagen, Venlo, Limburg, Netherlands) before qPCR 
amplification using miScript SYBR® Green PCR Kit 
(Qiagen) with the 7900HT Fast Real-Time PCR System 
(Applied Biosystems, Inc., Foster City, CA, USA). 
MiRNA and mRNA expression levels were normal-
ized to U6 small nuclear RNA (snRNA) and GADPH 
as internal controls, respectively, and were expressed 
as relative fold ratios. 
MiR-210 overexpression 
Transient transfections to achieve miR-210 
overexpression were conducted on 6-well plates at an 
initial density of 2.5 x 105 cells per well. At near con-
fluence, cells were treated with Lipofectamine® 
RNAiMAX Reagent diluted with either mirVana™ 
miRNA mimic (which overexpresses miR-210) or 
mirVana™ miRNA mimic Negative Control (as nega-
tive control) (all from Ambion®). 
Cell Proliferation Assay 
Cell proliferation was measured using the 3-(4, 
5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium 
bromide (MTT) assay (Sigma-Aldrich Corporation, St 
Louis, MO, USA). Cells were seeded onto 96-well 
plates at an initial density of 5000 cells per well and 
were cultured for 24 hours. Culture media were 
changed serially to reach various concentrations of 
TMZ (i.e. 0, 62.5, 125, 250, 500, 1000, 2000, and 3000 
μM). Cells were collected and the optical densities 
(OD) were measured at an absorbance wavelength of 
595 nm. The amount of cells viable relative to controls 
was calculated and the half-maximal inhibitory con-
centrations (IC50) were derived. Experiments were 
performed in triplicates. 
Statistical analysis 
Data analysis was performed using the Prism 
(version 6.0) software (Graphpad Software, Inc., La 
Jolla, CA, USA). Statistical significance was deter-
mined using student’s t-test and p-value < 0.05 was 
considered statistically significant. 
Results 
P4HB is upregulated and miR-210 is downreg-
ulated in chemoresistant GBM 
To verify the involvement of P4HB in GBM 
chemoresistance, and that miR-210 would be its 
potential regulator, their intrinsic expressions were 
quantified. As expected, P4HB expression was 
upregulated in the TMZ-resistant cells D54-R and 
U87-R by approximately 6-folds and 5-folds, 
respectively, when compared with the parental cells 
D54-S and U87-S (Fig. 1A). Conversely, the 
TMZ-resistant D54-R and U87-R cells expressed lower 
levels of miR-210 in comparison to their 
TMZ-sensitive counterparts by 2-folds and 10-folds, 
respectively, suggesting that P4HB may potentially be 
under the regulation of miR-210 (Fig. 1B).  
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Figure 1. P4HB is upregulated and miR-210 is downregulated in 
TMZ-resistant GBM cell lines. (A) Upregulation in the relative P4HB 
expression levels in TMZ-resistant GBM cell lines D54-R and U87-R when 
compared with those in the TMZ-sensitive D54-S and U87-S cells on qPCR. (B) 
Downregulations in miR-210 expression levels in D54-R and U87-R relative to 
those in D54-S and U87-S cells. (* = p < 0.05; *** = p < 0.001) 
 
P4HB and miR-210 expression levels in clinical 
glioma tissues 
 P4HB expressions were positively correlated 
with increasing tumour grades. P4HB expression was 
the highest in grade IV glioma at approximately 
150-folds, followed by grade III at 100-folds, when 
compared with grade II tumours (Fig. 2A). In contrast, 
miR-210 expressions were negatively correlated with 
that of P4HB in clinical glioma tumour samples. 
MiR-210 was the highest in grade II gliomas at ap-
proximately 4.5-folds, followed by grade III at ap-
proximately 2.4-folds, when compared with grade IV 
gliomas (Fig. 2B). 
MiR-210 overexpression downregulates P4HB 
in GBM cell lines 
We then overexpressed miR-210 to evaluate its 
potential regulatory action on P4HB. The transfection 
efficiency of the miR-210 mimic was confirmed by 
qPCR, which showed an increase in relative fold rati-
os by 100 times when compared with control (Fig. 
3A). Due to the intrinsically higher expression of 
miR-210 in the TMZ-sensitive cells, the absolute levels 
of miR-210 expression were higher in the parental 
D54-S and U87-S cells when compared to their re-
sistant counterparts. 
 
 
 
Figure 2. P4HB is upregulated and miR-210 is downregulated in 
higher grade clinical tumour samples. (A) Upregulation in the relative 
P4HB expression levels in grades III and IV glioma tumour samples when 
compared to those of grade II on qPCR. (* = p < 0.05; ** = p < 0.01 compared 
to grade II, respectively) (B) Downregulations in miR-210 expression levels in 
grades III and IV glioma tumour samples when compared to those of grade II 
glioma tumours sample. (* = p < 0.05; *** = p < 0.001 compared to grade IV, 
respectively) 
 
P4HB expressions at the mRNA levels were then 
determined after miR-210 overexpression. The latter 
caused P4HB downregulation by at least 2-folds when 
compared with negative controls in all four cell lines 
(Fig. 3B). Of note was that the absolute levels of P4HB 
expressions in the TMZ-resistant cell lines D54-R and 
U87-R remained higher in comparison to those of 
their respective TMZ-sensitive lines, due to the 
intrinciscally higher expression in the former group 
[7]. 
MiR-210 overexpression reduces chemo-
resistance in GBM cell lines 
With its effect of downregulating P4HB expres-
sion, we then examined whether miR-210 overex-
pression would diminish TMZ-resistance using the 
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MTT cell proliferation assay (Fig. 4). Except for U87-R, 
the IC50 of TMZ for cells transfected with negative 
controls was around 2000 μM. With miR-210 overex-
pression, the IC50 was reduced to about 200 μM and 
500 μM for the D54-S and U87-S cells, respectively, 
and at about 500 μM and 600 μM for the 
TMZ-resistant D54-R and U87-R cells, respectively. 
The overall findings were consistent with the sugges-
tion that P4HB would confer TMZ resistance in GBM, 
and that miR-210 overexpression may downregulate 
P4HB expression, resulting in greater response to 
TMZ cytotoxicity.  
Discussion 
The ERSR chaperone protein, P4HB, contributes 
to chemoresistance in GBM cells [15]. The current 
study explored miRNA interference as a potential 
therapeutic approach to downregulate P4HB expres-
sion for the potential restoration of chemosensivity in 
GBM towards TMZ. We found that miR-210 overex-
pression could achieve that in vitro in two commonly 
used cell lines. Interestingly, miR-210 is also widely 
reported to be an oncogene that is upregulated in 
various types of cancers, especially where intra-
tumoural hypoxia is common [16]. Our approach of 
using miR-210 overexpression to improve 
chemosentivity may therefore appear counterintui-
tive. It must be emphasized, however, that increased 
miR-210 expression was also found in non-malignant 
conditions, where hypoxia would be mild such as the 
placenta of pre-eclampsia patients. This has raised 
questions about the actual contributions of miR-210 
towards tumour aggression, as miR-210 overexpres-
sion may simply be a consequence of tumour hypoxia 
[16-18]. Moreover, miR-210 has been found to be 
downregulated in other neoplasms such as ovarian 
cancer, either due to decreased expression or genomic 
deletions [19, 20]. Repression of tumour cell growth 
initiation by miR-210 in human head and neck, as well 
as pancreatic cell lines has also been reported, sug-
gesting that miR-210 may potentially possess tumour 
suppressive characteristics as well as oncogenic ef-
fects [21].  
In fact, previous studies have reported miR-210 
to be associated with favourable prognostic outcomes. 
McCormick et al found the expression of miR-210 in 
clear cell renal cell cancer (CCRCC) to be associated 
with reduced proliferation, lower tumour grading, 
lower staging, and better patient survival, possibly 
due to the suppression of the von Hippel-Lindau 
(VHL) gene [22]. The initiation and progression of 
cancers depends on the expression of a wide variety 
of genes and their involvement in different cellular 
pathways. Each miRNA may have many different 
mRNA targets, and therefore can affect cellular pro-
cesses in different cell types differently. Similarly, 
miR-210 may target many genes that are involved in 
angiogenesis, cell proliferation and/or survival, and 
DNA damage repair [23]. To our knowledge, our 
study is the first to describe the interactions between 
the ERSR and miR-210, and the latter’s potential effect 
on chemoresponsiveness. Although miR-210 is widely 
known for its oncogenic effects, our findings provide 
a novel direction for future investigations. The latter 
may focus on the use of miRNA interference in the 
treatment of chemoresistant GBM in vivo. Important 
considerations include the effective delivery of 
miR-210 inhibitor and target specificity.  
 
 
 
Figure 3. MiR-210 regulates P4HB expression. (A) Transfection of 
miR-210 mimics successfully results in miR-210 overexpressions in all four GBM 
cell lines when compared with their respective negative controls on qPCR. (B) 
Downregulation in the relative P4HB expression levels occurs as the result of 
miR-210 overexpressions when compared to their respective negative controls. 
(** = p < 0.01; *** = p < 0.001) 
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Figure 4. MiR-210 upregulation may reduce chemoresistance in GBM cells. A decrease in IC50 of TMZ for cells with miR-210 overexpression (“+”) relative 
to its respective negative controls (“-“) in all four GBM cell lines used by MTT cell proliferation assay. 
 
Conclusions 
MiR-210 is commonly dysregulated in various 
cancers and serves as a useful prognostic biomarker. 
Our study demonstrated that miR-210’s inhibitory 
effects of P4HB could potentially reverse 
TMZ-resistance in GBM cells. Both ERSR and miR-210 
are known to affect malignant phenotypes in GBM. 
Our study is the first to demonstrate a potential link 
between them in determining chemosensitivity in 
GBM. The findings have important translational im-
plications in suggesting new directions of future 
studies for the treatment of chemoresistant GBM. 
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